Pathology & Laboratory Medicine

Publications

Filter By Faculty

Filter by Principal Investigator

2008

Li Y, Kang YS, Dai C, Kiss LP, Wen X, Liu Y. Epithelial-to-mesenchymal transition is a potential pathway leading to podocyte dysfunction and proteinuria. Am J Pathol. 2008;172(2):299-308.

Frasca F, Nucera C, Pellegriti G, Gangemi P, Attard M, Stella M, et al. BRAF(V600E) mutation and the biology of papillary thyroid cancer. Endocr Relat Cancer. 2008;15(1):191-205.

Andrade RS, Blondet JJ, Kast T, Jessurun J, Maddaus MA. Evaluation of isolated rib lesions with radionuclide-guided biopsy. Ann Thorac Surg. 2008;86(4):1111-4.

Jarboe EA, Folkins AK, Drapkin R, Ince TA, Agoston ES, Crum CP. Tubal and ovarian pathways to pelvic epithelial cancer: a pathological perspective. Histopathology. 2008;53(2):127-38.

Cairo S, Armengol C, de Reyniès A, Wei Y, Thomas E, Renard C-, et al. Hepatic stem-like phenotype and interplay of Wnt/beta-catenin and Myc signaling in aggressive childhood liver cancer. Cancer Cell. 2008;14(6):471-84.

Rand JH, Wu X-, Quinn AS, Chen PP, Hathcock JJ, Taatjes DJ. Hydroxychloroquine directly reduces the binding of antiphospholipid antibody-beta2-glycoprotein I complexes to phospholipid bilayers. Blood. 2008;112(5):1687-95.

Decaens T, Godard C, de Reyniès A, Rickman DS, Tronche F, Couty J-, et al. Stabilization of beta-catenin affects mouse embryonic liver growth and hepatoblast fate. Hepatology. 2008;47(1):247-58.

Setlur SR, Mertz KD, Hoshida Y, Demichelis F, Lupien M, Perner S, et al. Estrogen-dependent signaling in a molecularly distinct subclass of aggressive prostate cancer. J Natl Cancer Inst. 2008;100(11):815-25.

Arora N, Scognamiglio T, Zhu B, Fahey TJ. Do benign thyroid nodules have malignant potential? An evidence-based review. World J Surg. 2008;32(7):1237-46.

Heller KN, Arrey F, Steinherz P, Portlock C, Chadburn A, Kelly K, et al. Patients with Epstein Barr virus-positive lymphomas have decreased CD4(+) T-cell responses to the viral nuclear antigen 1. Int J Cancer. 2008;123(12):2824-31.